MedTrace Logo

PNU 166148 in Treating Patients With Metastatic Solid Tumors

NCT00004076 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of PNU 166148 in treating patients who have metastatic solid tumors that have not responded to previous treatment.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

mureletecan

Sponsors & Collaborators

  • University of Glasgow

    lead OTHER

Principal Investigators

  • Chris Twelves, MD, BMedSci, FRCP · University of Glasgow

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004076 on ClinicalTrials.gov